Skip to content
On this page:OverviewPublicationsResearchersInstitutionsOpen access
PICO Portalanswers from OpenAlex

International Breast Cancer Study Group

InstitutionResearch output, impact & collaborations

International Breast Cancer Study Group is a institution indexed in PICO Portal from OpenAlex.

What is known about International Breast Cancer Study Group?

PICO Portalrecord summary

International Breast Cancer Study Group is a research organisation in Bern, CH. OpenAlex records 884 works and 257,054 citations for it. 223 researchers list it as their most recent affiliation.

How many works does International Breast Cancer Study Group have?

PICO Portalindexed works

International Breast Cancer Study Group has 884 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does International Breast Cancer Study Group have?

PICO Portalcitation count

International Breast Cancer Study Group has 257,054 citations in the OpenAlex counts PICO Portal stores.

How many researchers are at International Breast Cancer Study Group?

PICO Portalresearcher count

International Breast Cancer Study Group has 223 researchers in the PICO Portal index.

What is the average h-index at International Breast Cancer Study Group?

PICO Portalavg h-index

International Breast Cancer Study Group has an average h-index of 85 in OpenAlex.

What is the ROR of International Breast Cancer Study Group?

PICO Portalror

The ROR for International Breast Cancer Study Group is on the source record.

What is the OpenAlex record for International Breast Cancer Study Group?

PICO Portalopenalex

The OpenAlex for International Breast Cancer Study Group is on the source record.

Who are the most-cited researchers behind International Breast Cancer Study Group?

PICO Portaltop researchers by citations
1
Rolf A. Stahel · Lung Cancer Treatments and Mutations
547 works29,247 citations

What are the most-cited papers on International Breast Cancer Study Group?

PICO Portalmost cited works
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier
The Lancet Oncology. 2019481 Citations
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K.M. Kerr, L. Bubendorf, Martin J. Edelman, Andrea Ascoli Marchetti, Tony Mok, Silvia Novello, Kenneth J. O’Byrne, Rolf A. Stahel, Solange Peters, Enriqueta Felip, Rolf A. Stahel, Enriqueta Felip, Solange Peters, Keith M. Kerr, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Martin J. Edelman, Tony Mok, Kenneth J. O’Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz‐Ares, Egbert F. Smit, Peter Meldgaard, Alex A. Adjei, M. Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre‐Finn, Gaetano Rocco, Giulia Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, W. Weder, Dirk De Ruysscher, C. Le Péchoux, Paul De Leyn, Virginie Westeel
Annals of Oncology. 2014300 CitationsOPEN ACCESS
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe
Clinical Cancer Research. 2018231 CitationsOPEN ACCESS

How much of the research on International Breast Cancer Study Group is open access?

PICO Portalopen access share
67%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
0%
Bronze
67%
Closed
33%

Related on PICO Portal

470M+ articles · 14-day free trial